| Title |
Immunotherapy for the Management of Advanced Melanoma: The Next Steps
|
|---|---|
| Published in |
American Journal of Clinical Dermatology, March 2013
|
| DOI | 10.1007/s40257-013-0013-0 |
| Pubmed ID | |
| Authors |
Dragoslav Zikich, Jacob Schachter, Michal J. Besser |
| Abstract |
Melanoma is an immunogenic tumor that can induce a natural immune response. A number of immunotherapy-based approaches have been developed over the past decades, and certain degrees of effectiveness were achieved by the use of cytokines, adoptive cell transfer and T-cell immune modulators. Currently, interleukin-2 and the immune stimulatory antibody, ipilimumab, are the only two approved immunotherapies for metastatic melanoma, but various new therapies are in promising developmental stages. This comprehensive review will discuss the latest achievements of immunotherapy and emerging directions for the management of advanced melanoma. |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Unknown | 30 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 16% |
| Student > Master | 5 | 16% |
| Student > Bachelor | 4 | 13% |
| Student > Doctoral Student | 3 | 10% |
| Researcher | 2 | 6% |
| Other | 7 | 23% |
| Unknown | 5 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 32% |
| Agricultural and Biological Sciences | 5 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 13% |
| Immunology and Microbiology | 3 | 10% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Other | 1 | 3% |
| Unknown | 6 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2013.
All research outputs
#20,185,720
of 22,701,287 outputs
Outputs from American Journal of Clinical Dermatology
#887
of 973 outputs
Outputs of similar age
#172,773
of 197,559 outputs
Outputs of similar age from American Journal of Clinical Dermatology
#9
of 13 outputs
Altmetric has tracked 22,701,287 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 973 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,559 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.